Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T16:43:11.596Z.
Calculation as of: 2026-10-06T16:43:11.596Z.
Quote observation: 2026-10-06T16:40:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76fc2c3b696fe1037033af5d10d354cd3b8573abd6cfebee9ff2ae185940ee40
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$2.41B
Price/OCF Ratio
31.25
TTM Avg
37.03
3Y Avg
38.41
5Y Avg
35.77
Market Cap
$2.39B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.38B
Price/OCF Ratio
17.39
TTM Avg
42.28
3Y Avg
63.13
5Y Avg
63.13
Market Cap
$2.36B
Price/OCF Ratio
N/A
TTM Avg
54.75
3Y Avg
54.75
5Y Avg
54.75
Market Cap
$2.31B
Price/OCF Ratio
29.29
TTM Avg
83.65
3Y Avg
83.65
5Y Avg
83.65
Market Cap
$2.29B
Price/OCF Ratio
6.45
TTM Avg
6.21
3Y Avg
8.19
5Y Avg
14.19
Market Cap
$2.28B
Price/OCF Ratio
N/A
TTM Avg
35.55
3Y Avg
17.39
5Y Avg
17.83
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Disc Medicine, Inc. (IRON) | $2.43B | N/A | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.41B | 31.25 | 37.03 | 38.41 | 35.77 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.39B | N/A | N/A | N/A | N/A |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.39B | N/A | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.38B | 17.39 | 42.28 | 63.13 | 63.13 |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.36B | N/A | 54.75 | 54.75 | 54.75 |
| Liquidia Corporation (LQDA)vs › | $2.31B | 29.29 | 83.65 | 83.65 | 83.65 |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.29B | 6.45 | 6.21 | 8.19 | 14.19 |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.28B | N/A | 35.55 | 17.39 | 17.83 |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.58B | N/A | 8.27 | 8.27 | 8.27 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
